NeuroSense Therapeutics (NASDAQ:NRSN) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research note released on Wednesday,Benzinga reports. The brokerage currently has a $14.00 price objective on the stock.

A number of other equities analysts also recently commented on the company. Roth Mkm began coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price objective on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

NeuroSense Therapeutics Stock Performance

Shares of NASDAQ NRSN opened at $0.77 on Wednesday. NeuroSense Therapeutics has a one year low of $0.63 and a one year high of $2.60. The business’s 50-day moving average price is $0.90 and its two-hundred day moving average price is $1.01.

Hedge Funds Weigh In On NeuroSense Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics in the second quarter valued at approximately $54,000. Squarepoint Ops LLC boosted its holdings in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares during the period. Two Sigma Investments LP bought a new stake in shares of NeuroSense Therapeutics during the 3rd quarter worth $26,000. Finally, Yorkville Advisors Global LP acquired a new position in NeuroSense Therapeutics in the 4th quarter valued at $77,000. Institutional investors and hedge funds own 1.04% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.